

Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England

Samuel Clifford PhD^{1,2}, Pauline Waight BSc³, Jada Hackman BSc^{1,2}, Stephane Hué PhD^{1,2}, Charlotte M Gower DPhil³, Freja CM Kirsebom PhD³, Catriona Skarnes MSc³, Louise Letley MSc³, Jamie Lopez Bernal PhD³, Nick Andrews PhD³, Stefan Flasche PhD^{1,2,+}, Elizabeth Miller FRCPATH^{2,3,+}

1. Centre for mathematical modelling of infectious diseases, London School of Hygiene & Tropical Medicine, LONDON WC1E 7HT
2. Department for infectious disease epidemiology, London School of Hygiene & Tropical Medicine, LONDON WC1E 7HT
3. National Infection Service, UK Health Security Agency, LONDON NW9 5EQ

+ Contributed equally

Corresponding author, Liz.Miller@lshtm.ac.uk, LSHTM, UK HSA

Appendix

Patient characteristics

Table A1: Number of contacts with listed vaccine status for each case vaccine status. Numbers in brackets show the additional individuals included in the sensitivity analysis.

| Case | 1 ChAdOx1 | 2 ChAdOx1 | 1 BNT162b2 | 2 BNT162b2 | None |
|------------|-----------|-----------|------------|------------|--------|
| 1 ChAdOx1 | 17 (4) | 1 | 3 | 4 | 23 (5) |
| 2 ChAdOx1 | 2 (1) | 26 (5) | 7 (1) | 12 (1) | 21 (9) |
| 1 BNT162b2 | 6 | 1 | 15 (2) | 2 | 33 (2) |
| 2 BNT162b2 | 9 | 8 | 4 | 10 | 9 |
| None | 6 | 2 | 4 | 5 | 48 (2) |


Cross-tabulation of contact vaccine status by household index case status is shown in Table A1,

21 indicating that household contacts tend to have either the same vaccine status (product and
 22 number of doses) as their index cases or were not vaccinated at the time of data collection. Index
 23 cases who were unvaccinated rarely had household members who were vaccinated.

24 Table A2: Number of index cases and their household contacts with listed vaccine status for each
 25 age group. Numbers in brackets show the additional individuals included in the sensitivity
 26 analysis. There are no index cases younger than 18.

| Status | Vaccine | <18 | 18-49 | 50-64 | 65+ |
|---------|------------|--------|--------|--------|-------|
| Case | 1 ChAdOx1 | 0 | 15 (2) | 17 (2) | 3 (1) |
| | 2 ChAdOx1 | 0 | 20 (3) | 26 (4) | 1 |
| | 1 BNT162b2 | 0 | 22 (1) | 13 (2) | 2 |
| | 2 BNT162b2 | 0 | 13 | 17 | 1 |
| | None | 0 | 33 | 12 (1) | 0 |
| Contact | 1 ChAdOx1 | 0 (1) | 13 (2) | 22 (2) | 5 |
| | 2 ChAdOx1 | 0 | 13 (2) | 22 (2) | 3 (1) |
| | 1 BNT162b2 | 0 | 22 (2) | 9 | 2 (1) |
| | 2 BNT162b2 | 0 | 14 (1) | 16 | 3 |
| | None | 67 (7) | 55 (8) | 11 (2) | 1 (1) |

27




28

29 Figure A1: Distribution of contacts' observed serial intervals (grey bars). The black density curve
 30 represents the skewed normal distribution fit to the observed data, and its median and 95% range
 31 are shown as the black circle and line, respectively. The main analysis omits 16 households where

32 any contact's serial interval is more negative than -2 days.


33

34 Prevalence of lineages



35

36 Figure A2: A) Weekly proportions of sequenced swabs from Pillar 2 testing that were Alpha,
37 Delta, Other (known but not Alpha or Delta) or had no detected lineage. Only weeks after the
38 commencement of the study are shown. B) Logistic regression model fit to the Alpha and Delta
39 lineage swabs showing what proportion of these have Delta lineage (including AY sublineages of
40 Delta).



41

42 Figure A3: Lineage associated with each household, either through sequencing of study swabs
 43 (filled circles) or inferred through the model in Figure A2 (open circles). Inferred probability of
 44 Delta lineage is at time of the Day 1 swabs.

45 Identification of non-household transmission

46 Whole-genome Illumina reads were retrieved from the European Nucleotide Database under the
 47 accession PRJEB37886. (<https://www.ebi.ac.uk/ena/browser/view/PRJEB37886>). Consensus
 48 genomes were generated using the Snippy pipeline mapping to the reference genome
 49 NC_045512.2.¹ Highly ambiguous and/or homoplasic sites were masked in the consensus
 50 alignment as described by de Maio et al.² A maximum-likelihood phylogeny was reconstructed
 51 from the consensus genomes under the Hasegawa-Kishino-Yano (HKY) model of nucleotide
 52 substitution with 1,000 ultrafast bootstrap replicates to assess branch supports and visualized in
 53 iTOL.^{3,4}

54 ClusterPicker was used to identify clusters of transmission in the phylogeny.⁵ These were defined
 55 as clusters of sequences with patristic distances of no more than 2 SNP (6.6×10^{-5}
 56 substitutions/site)⁶ and bootstrap support of at least 70%.

57 Model of Secondary Attack Rate

58 For the model of secondary attack rate the likelihood is

$$\begin{aligned}
 y_i &\sim \text{Bern}(p_i) \\
 \log\left(\frac{p_i}{1-p_i}\right) &= \beta_0 + \delta_{V_i} + \\
 59 &\beta_{1,v_i,V_i}\mathbf{I}(d_{1,i,\text{contact}} \geq k_1) + \beta_{2,v_i,V_i}\mathbf{I}(d_{2,i,\text{contact}} \geq k_2) + \\
 &\gamma_{1,v_i,V_i}\mathbf{I}(d_{1,i,\text{case}} \geq k_1) + \gamma_{2,v_i,V_i}\mathbf{I}(d_{2,i,\text{case}} \geq k_2) + \\
 &\varepsilon_{\text{contact}}\mathbf{I}(A_{i,\text{contact}} < a_{\text{contact}}) + \varepsilon_{\text{case}}\mathbf{I}(A_{i,\text{case}} \geq a_{\text{case}})
 \end{aligned}$$

60 where \mathbf{I} is an indicator function which is 1 when its input is true and 0 otherwise and $d_{j,i,c}$ is the
61 number of days since the j th dose of vaccine product v was given to either contact i or their
62 household index case (indexed by c) who is infected with variant V_i . A fixed effect, δ , accounts
63 for the increased infectivity of Delta beyond that of Alpha. Protection afforded by dose j is
64 assumed to begin after $k = \{21,7\}$ days. These are currently fixed but a distribution may be used
65 instead if there is some observed variability we wish to include. Age effects, ε , are assumed to be
66 non-zero when the contact is younger than $A_{i,\text{contact}} = 18$ and when the case is at least as old as
67 $A_{i,\text{case}} = 50$. Where V_i was missing due to that household's swabs not being sequenced, it was
68 sampled at each step of the MCMC from a Bernoulli distribution with its single parameter
69 representing the modelled proportion of sequenced Pillar 2 swabs with Delta lineage at time of
70 that household's Day 1 swabs.

71 The priors for the model parameters associated with transmission reduction are parameterised as
72 weakly informative normal distributions (with means and precision ($\tau = \sigma^{-2}$))

$$\begin{aligned}
 \gamma_{j,v,V} &\sim \mathcal{N}(\gamma_{j,0,V}, \tau_\gamma) \\
 \gamma_{j,0,V} &\sim \mathcal{N}(0, 10^6) \\
 \tau_\gamma &= \sigma_\gamma^{-2} \\
 73 \quad \sigma_\gamma &\sim \text{Exp}(0.3)
 \end{aligned}$$

74 The penalised complexity prior on the standard deviation implies a prior probability of it
75 exceeding 10 of 0.05.²⁴

76 For the infection protection parameters, informative priors are derived from reported vaccine
77 efficacy of the two vaccine products against the Alpha (B.1.1.7) and Delta (B.1.617.2) variants of
78 SARS-CoV-2.⁸ The priors are normally distributed for the log-odds ratios, with mean and

79 precision parameters,

80

$$\begin{aligned} \beta_{1,1,A} &\sim \mathcal{N}(\log 0.5, 2) & \beta_{1,1,D} &\sim \mathcal{N}(\log 0.65, 2) \\ \beta_{1,2,A} &\sim \mathcal{N}(\log 0.43, 0.25) & \beta_{1,2,D} &\sim \mathcal{N}(\log 0.67, 0.25) \\ \beta_{2,1,A} &\sim \mathcal{N}\left(\log \frac{0.25}{0.5}, 2\right) & \beta_{2,1,D} &\sim \mathcal{N}\left(\log \frac{0.33}{0.65}, 2\right) \\ \beta_{2,2,A} &\sim \mathcal{N}\left(\log \frac{0.06}{0.43}, 0.25\right) & \beta_{2,2,D} &\sim \mathcal{N}\left(\log \frac{0.12}{0.67}, 0.25\right) \end{aligned}$$

81

82 Here we have taken the point estimates of the log odds ratios and scaled the standard errors up by
83 a factor of 2, rounding to the nearest 0.5, in order to provide informative priors with additional
84 variance that ensure that the posteriors are still sensitive to the data. As the $\beta_{2,v,V}$ represent the
85 marginal effect of the second dose, we derive $B_{2,v,V} = \beta_{1,v,V} + \beta_{2,v,V}$, the log-odds of the effect of
86 double vaccination against variant V with vaccine product v .

87 The effects of age have informative priors derived from Davies et al. for under-18s acquiring
88 infection, $\varepsilon_{\text{contact}} \sim N(\log 0.50, 24)$, and from Yousaf et al.¹⁶ cited in Goldstein et al.¹¹ for case
89 transmission, $\varepsilon_{\text{case}} \sim N(\log 1.86, 4.67)$.

90 To determine how informative the priors above are, we replace the informative priors above for
91 all $\beta_{j,v,V}$ with a weakly informative $N(0, \sigma_\beta^{-2})$ prior with $\sigma_\beta \sim \text{Exp}(0.3)$ and the effects of age
92 each having a weakly informative $N(0, 10^{-6})$ prior.

93 Sensitivity analysis

94 Sensitivity analysis for the models described above was carried out by including all households,
95 regardless of serial intervals. An additional 16 household index cases were included (all of which
96 tested positive during the study) which contributed an additional 32 household contacts (of
97 whom 23 tested positive). Sequences were available for mine of these additional index cases and
98 ten of the contacts. Unless otherwise stated, the parameters given here represent transmission of a
99 Delta infection from a non-elderly adult to an adult, neither of whom are vaccinated.

100 The additional infectiousness of Delta over Alpha was similar between the main (Risk Ratio: 1.64
101 (1.15, 2.44)), sensitivity analysis (1.58 (1.18, 2.21)), and model with weakly informative priors for


102 all model effects (1.68 (1.17, 2.49)).

103 Age effects were comparable across the analyses (Table A3), The posteriors for the effect of age
104 for child contacts in the main and sensitivity analyses is the same as the informative prior (to one
105 decimal place) but even using the weakly informative prior the median and 2.5th percentile match
106 those results. For 50+ year old adult index cases, the increase in infectivity is broadly similar for
107 the main and sensitivity analyses, with the median similar to that of the informative prior used in
108 its estimation. The posterior precision for the log-odds from the main and sensitivity analyses is
109 approximately 17 and 19, respectively, compared to approximately 5 in the prior and 13 when
110 using the weakly informative prior. So in the main analysis, the median may not have shifted
111 much but there is more precision in the estimate.

112 Table A3: Posterior median risk ratios (and 95% CrIs) for effects of age, by analysis. *The
113 Informative prior row is draws from the prior only.

| Analysis | Case 50+ | Contact <18 |
|-------------------------------------|----------------|----------------|
| Main | 1.1 (1.0, 1.2) | 0.8 (0.7, 1.0) |
| Sensitivity | 1.1 (1.0, 1.2) | 0.8 (0.7, 1.0) |
| Main with weakly informative priors | 1.1 (1.0, 1.2) | 0.9 (0.6, 1.0) |

114



115

116 Figure A4: Odds Ratios (exponentiated regression coefficients) for effect of vaccination on
 117 transmission reduction in cases and protection against infection of contacts for main and
 118 sensitivity analysis (Sensitivity = all individuals, Flat priors = Main but with weakly informative
 119 priors), as well as ORs derived from sampling the priors (Priors). The 95% credible intervals for
 120 transmission reduction priors are $[0, \infty)$.

121 Table A4: Vaccine effectiveness against transmission reduction in cases and protection against
 122 infection of contacts for main and sensitivity analysis (Sensitivity = all individuals, Flat priors =

| Analysis | Variant | Vaccine | Doses | Infection protection | Transmission reduction |
|-------------|---------|----------|-------|----------------------|------------------------|
| Main | Alpha | ChAdOx1 | 1 | 3% (-38%, 39%) | -7% (-60%, 29%) |
| | | | 2 | 26% (-39%, 73%) | 35% (-26%, 74%) |
| | | BNT162b2 | 1 | 53% (7%, 83%) | 26% (-11%, 54%) |
| | | | 2 | 71% (12%, 95%) | 57% (5%, 85%) |
| | Delta | ChAdOx1 | 1 | 2% (-19%, 31%) | 14% (-11%, 52%) |
| | | | 2 | 14% (-5%, 46%) | 42% (14%, 69%) |
| | | BNT162b2 | 1 | 4% (-21%, 44%) | 9% (-16%, 49%) |
| | | | 2 | 24% (-2%, 64%) | 31% (-3%, 61%) |
| Sensitivity | Alpha | ChAdOx1 | 1 | 10% (-27%, 43%) | -4% (-55%, 28%) |
| | | | 2 | 36% (-23%, 76%) | 26% (-27%, 63%) |
| | | BNT162b2 | 1 | 61% (19%, 87%) | 21% (-20%, 50%) |
| | | | 2 | 74% (20%, 96%) | 51% (7%, 82%) |
| | Delta | ChAdOx1 | 1 | 4% (-16%, 34%) | 8% (-15%, 41%) |
| | | | 2 | 19% (-1%, 49%) | 30% (6%, 55%) |
| | | BNT162b2 | 1 | 9% (-14%, 49%) | 6% (-16%, 37%) |
| | | | 2 | 39% (7%, 72%) | 25% (-2%, 54%) |
| Flat priors | Alpha | ChAdOx1 | 1 | -5% (-49%, 22%) | -6% (-64%, 34%) |
| | | | 2 | -4% (-64%, 44%) | 44% (-22%, 78%) |
| | | BNT162b2 | 1 | 21% (-8%, 65%) | 29% (-10%, 58%) |
| | | | 2 | 27% (-11%, 79%) | 61% (10%, 87%) |
| | Delta | ChAdOx1 | 1 | 0% (-21%, 22%) | 16% (-12%, 53%) |
| | | | 2 | 2% (-14%, 28%) | 51% (24%, 73%) |
| | | BNT162b2 | 1 | 1% (-14%, 25%) | 13% (-14%, 55%) |
| | | | 2 | 5% (-10%, 39%) | 40% (8%, 65%) |

124

125 In the sensitivity analysis, no longer excluding households with extreme serial intervals, the only
126 qualitative difference in conclusion, at 95% credibility, is that 2 doses of BNT162b2 protects
127 contacts against infection against Delta lineage SARS-CoV-2 (the only vaccine status to do so)
128 with a VE of 39% (95%: 7%, 72%) (Table A4). in the main analysis the median suggests a moderate
129 effect but there is sufficient uncertainty in the estimate that it is difficult to distinguish from no
130 effect (VE: 24%, 95%: -2%, 64%).


131 Table A5: Ratios of risk ratios for the effect of BNT162b2 vs ChAdOx1 for protection against
132 infection of an adult contact (where case is unvaccinated) and transmission from a non-elderly

133 adult cases to an unvaccinated adult contact.

| Variant | Dose | Infection protection | Transmission reduction |
|---------|------|----------------------|------------------------|
| Alpha | 1 | 0.47 (0.16, 1.03) | 0.73 (0.41, 1.04) |
| | 2 | 0.40 (0.06, 1.70) | 0.74 (0.22, 1.64) |
| Delta | 1 | 0.97 (0.56, 1.41) | 1.02 (0.65, 1.69) |
| | 2 | 0.90 (0.49, 1.32) | 1.15 (0.80, 1.88) |


134

135 Sensitivity analysis indicates the same patterns of secondary attack rate by vaccination status hold
 136 for the default age group (Figure 2), with the exception of SARs that are approximately 0.1
 137 (absolute value) higher for Delta households where the index case has received two doses of
 138 ChAdOx1 and the contact is either unvaccinated or has received at least one dose of ChAdOx1
 139 (Figure A5). These differences still indicate that vaccinating index cases with two doses of
 140 ChAdOx1 is effective in reducing the SAR of Delta infections and the reduction for two doses is
 141 comparable in ChAdOx1 and BNT162b2. Figure A6 reflects that SARs are lower when the
 142 contact is a child and higher when the case is an adult over 50.



143

144 Figure A5: Main analysis shown in Figure 2, for each combination of index cases aged 18-49
 145 and 50+ and contacts aged <18 and 18+. Large numbers inside cells are the median secondary
 146 attack rate (SAR), with the small numbers below and above corresponding to the 95%
 147 credible interval.



148

149

150

151

152

Figure A6: Sensitivity analysis (no households excluded for extreme serial intervals) of predicted secondary attack rates (as in Figure A5) for each combination of vaccine status of case and contact and each combination of index cases aged 18-49 and 50+ and contacts aged <18 and 18+.

153

Infection history dynamics


154

We investigated PCR positivity after onset of symptoms for both cases and contacts by fitting a generalised linear mixed effects model with Bernoulli likelihood to each of the four vaccination groups. We assumed a quadratic effect for time since onset of symptoms, with random effect parameters by vaccine group (weakly informative priors with mean zero), to allow a rise from pre-exposure negativity, and a random intercept for each individual to account for their repeated measurement. Comparison was made against the no vaccination group.

160

The (up to) three swabs per individual were not part of routine surveillance with regular swabbing, and so negative swabs prior to the infecting exposure were unavailable. Therefore as part of the MCMC routine we sampled, at each step, an incubation period from $\Gamma(\alpha = 3.20, \beta = 0.56)$, being the distribution that matches a median of 5.1 days and 95th percentile of 11.7 days¹², and use this as a pseudo-absence (95% interval: 1.3, 13.4 days prior to onset of symptoms). Where the first test occurs prior to the onset of symptoms, the sampled incubation period distribution was truncated to the time of the first test to ensure that the infecting exposure occurred prior to both onset of symptoms and first positive test.

167



168

169

170 Figure A7: Relative risk of PCR positivity by Variant and vaccination status for symptomatic
 171 infections (index cases recruited from Pillar 2 testing and the symptomatic household
 172 contacts they infected). Lines represent median trajectories and the ribbon is the 95% credible
 173 interval.

174 References

175 1. Seemann, T. Rapid haploid variant calling and core genome alignment.
 176 <https://github.com/tseemann/snippy> (2020).

177 2. De Maio, N. *et al.* *Masking strategies for SARS-CoV-2 alignments.*
 178 <https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480> (2020).

179 3. Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective
 180 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol. Biol. Evol.* **32**, 268–
 181 274 (2015).

182 4. Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree

183 display and annotation. *Nucleic Acids Res.* **49**, W293–W296 (2021).

184 5. Ragonnet-Cronin, M. *et al.* Automated analysis of phylogenetic clusters. *BMC Bioinformatics*
185 **14**, 317 (2013).

186 6. Lythgoe, K. A. *et al.* SARS-CoV-2 within-host diversity and transmission. *Science* **372**,
187 eabg0821 (2021).

188 7. Simpson, D., Rue, H., Riebler, A., Martins, T. G. & Sørbye, S. H. Penalising Model
189 Component Complexity: A Principled, Practical Approach to Constructing Priors. *Stat. Sci.*
190 **32**, 1 – 28 (2017).

191 8. Lopez Bernal, J. *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
192 *N. Engl. J. Med.* (2021) doi:10.1056/nejmoa2108891.

193 9. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in
194 England. *Science* (2021) doi:10.1126/science.abg3055.

195 10. Yousaf, A. R. *et al.* A Prospective Cohort Study in Nonhospitalized Household Contacts With
196 Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Symptom Profiles and Symptom
197 Change Over Time. *Clin. Infect. Dis.* **73**, e1841–e1849 (2021).

198 11. Goldstein, E., Lipsitch, M. & Cevik, M. On the Effect of Age on the Transmission of SARS-
199 CoV-2 in Households, Schools, and the Community. *J. Infect. Dis.* **223**, 362–369 (2021).

200 12. McAloon, C. *et al.* Incubation period of COVID-19: a rapid systematic review and meta-
201 analysis of observational research. *BMJ Open* **10**, (2020).

202